Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. - Wikidata - wikimedia - TriplyDB

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.

http://www.wikidata.org/entity/Q33250432

about

EGFR Signaling in Liver Diseases EGFR expression in gallbladder carcinoma in North America.Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.Current management of gallbladder carcinoma.Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma EGFR and HER2 expression in advanced biliary tract cancer.Targeted therapy in biliary tract cancer: 2009 update.Genetics of biliary tract cancers and emerging targeted therapies.Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.Targeted therapy for biliary tract cancers.Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma.

P2860

Q26771265-F2CEEDD8-B682-4987-AD17-8844359DC5C4 Q33372792-9E295A28-8B9C-45EE-B43E-DCB7AF55293F Q33611056-9F9CA6E6-FC07-4055-994E-765AE34EA1AD Q33723528-794C49BD-5907-4FF5-87C1-F38FEAE241B8 Q35583920-429D6540-223B-437F-BC69-C19E3891447C Q36614705-6AAAB39B-883D-4987-A7D8-7DDAFDBD4C73 Q37351498-E9AA31CF-5511-4776-B0D4-2928B2205F46 Q37362858-1B12D498-BEB4-472D-9BA5-4ACAB14D42B5 Q37650623-943E052D-BAF3-4EF7-99EE-D9BCA67CED2E Q37765099-51D68638-2CB9-4455-858E-F6FA4ADBE307 Q37833005-8B526E11-1D6B-4C46-B947-C11B8A60FF70 Q37866791-55DDC6A2-913D-4E01-819B-8CE9C3D0BA8B Q37982650-707E26ED-0A48-4BDE-B7AD-5DC662DB0AA4 Q39647813-8139A5C6-7DE9-4987-9555-69A96394398D Q47118575-50702197-0136-4916-B4CD-F9510A907C39

P2860

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.

http://www.wikidata.org/entity/Q33250432

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Gemcitabine in combination wit ...... angiocarcinoma: a case report.

@ast

Gemcitabine in combination wit ...... angiocarcinoma: a case report.

@en

type

label

Gemcitabine in combination wit ...... angiocarcinoma: a case report.

@ast

Gemcitabine in combination wit ...... angiocarcinoma: a case report.

@en

prefLabel

Gemcitabine in combination wit ...... angiocarcinoma: a case report.

@ast

Gemcitabine in combination wit ...... angiocarcinoma: a case report.

@en

P1433

Q33250432-B3945EE8-D3E9-4FB3-B7D6-7B8EA84F540A

P1476

Q33250432-9C1088F0-C738-4586-BD71-F3286EBD2E11

P2093

Q33250432-0F471744-CA3D-42F5-8710-34BDB7265F95

Q33250432-36F5AAE9-D47E-4026-A033-DC275C6AFDD2

Q33250432-EDE143BA-0067-40EC-98EB-F3333967F0BC

Q33250432-EEF78178-E73E-4EEA-A507-0D1C3495E802

Q33250432-F56BF5F5-60ED-42B4-8DC1-BEA5C7559CD3

Q33250432-FE3C28CC-2A20-4E7A-B17A-E419AFF84EE6

P2860

Q33250432-018839B2-AD5F-40D5-9524-9EB36BF6E234

Q33250432-1E678E8C-B6C6-463E-9F2A-770411826EB6

Q33250432-28CDEA23-16BC-47EA-B56A-E837712EF4D1

Q33250432-331A0C01-5025-4CA8-933B-6AA35359658E

Q33250432-34D8885F-7D32-42CF-975E-C9C6B74B2474

Q33250432-4C75E927-3ACB-4BE8-B11C-5C43C24FFFF1

Q33250432-62B88390-AFEC-4FFE-A76D-794078A4CAA2

Q33250432-6D39525E-78CC-4950-8F6B-8CAB32B7D325

Q33250432-81EE4C22-5F0A-4441-A4D4-A65BDD41B8A6

Q33250432-8ECD282D-FE27-4615-8AEF-D7847FCE3DCA

P2888

Q33250432-A0008BAF-5EF0-4605-A890-06C4292A7491

P304

Q33250432-B83C394B-6232-428A-8B07-70996A26A632

P31

Q33250432-2BB5BEE2-CA82-481E-ACFC-1EE0B1E65181

P356

Q33250432-4FD4A316-4CD4-474C-A06B-C74A5BA17014

P407

Q33250432-4533FA93-81BB-4C45-9434-6EC356427D3D

P478

Q33250432-7D4788B3-E219-4AB5-93D4-E466B0151107

P577

Q33250432-CEAB8D1D-EE37-45F4-BC52-084C18376D4F

P5875

Q33250432-25ABDF15-EDEC-4C0C-B148-01F7CE5C89EC

P6179

Q33250432-B9A8B5F3-F5AA-43E9-8B76-52D600E8A762

P698

Q33250432-AAE95364-1F96-4829-938E-D671F5B6F0F7

P921

Q33250432-061AD1F6-C9B2-4918-A101-DF6C63EC898A

Q33250432-4430DB9A-8E78-4B2C-B5EC-A58495532757

Q33250432-E57F67DA-4AE2-4F01-93BF-E2B2043924E8

P932

Q33250432-3433E628-CBF4-46D9-86C1-02693B030D35

P356

1471-2407-6-190

P1433

P1476

Gemcitabine in combination wit ...... angiocarcinoma: a case report.

@en

P2093

Carl C Schimanski

http://www.w3.org/2001/XMLSchema#string

Markus Moehler

http://www.w3.org/2001/XMLSchema#string

Martin F Sprinzl

http://www.w3.org/2001/XMLSchema#string

Peter R Galle

http://www.w3.org/2001/XMLSchema#string

Simin Schadmand-Fischer

http://www.w3.org/2001/XMLSchema#string

Stephan Kanzler

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

The role of chemotherapy in cholangiocarcinoma.

Epidermal growth factor receptor (EGFR) signaling in cancer.

P2888

1471-2407-6-190

P304

190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-6-190

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26441761

http://www.w3.org/2001/XMLSchema#string

P6179

1005033212

http://www.w3.org/2001/XMLSchema#string

P698

16846514

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

1564184

http://www.w3.org/2001/XMLSchema#string